Biotechnology company Odyssey Therapeutics (ODTX.US) has filed to go public in the United States, aiming to raise $100 million.

Odyssey Therapeutics, a biotechnology company focused on patients with autoimmune and inflammatory diseases, filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) on Friday, seeking to raise $100 million. The company plans to list on the Nasdaq under the ticker "ODTX". Odyssey Therapeutics is developing drugs aimed at precisely targeting the disease pathology. Its most advanced candidate, OD-07656, is a small molecule scaffold inhibitor of receptor interacting protein kinase 2. The company plans to start a 2a phase single agent trial for ulcerative colitis in the first quarter of 2025 and a 2a phase combination trial with vedolizumab in the first half of 2026. Its pipeline also includes two preclinical projects: a small molecule scaffold inhibitor of interleukin-1 receptor associated kinase 4 and a protein agonist targeting tumor necrosis factor receptor 2. The Boston, Massachusetts-based company was founded in 2021. Its collaboration revenue over the past 12 months ended September 30, 2024, was $3 million.